Monday, February 16, 2026 2/16/2026

Impact of TCR-pMHC affinity on prostate-specific CD4+ T cell development and function

Award Number: F30CA247264
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 01/01/2020
PERIOD OF PERFORMANCE END DATE: 12/30/2022

Group Awards By:

View Award Description

Impact of TCR-pMHC affinity on prostate-specific CD4+ T cell development and function - PROJECT SUMMARY/ABSTRACT Foxp3+ CD4+ regulatory T (Treg) cells are critical for the prevention of autoimmunity and the regulation of antitumor immunity, functioning in part by suppressing the activation and function of conventional T cells. Treg cells depend on T cell receptor (TCR) stimulation for many facets of their biology, including thymic development, peripheral differentiation, and suppressive function. In this regard, the affinity of TCR binding to self-peptides complexed with MHC class II molecules (self-pMHCII) is thought to be a primary determinant of Treg cell development and function. Existing models of thymic selection posit that intermediate TCR-pMHCII affinities – at the threshold between positive and negative selection – promote optimal thymic Treg (tTreg) development, allowing Treg cell clones to differentiate while also evading clonal deletion. In addition, it has been suggested that Treg cells may be more sensitive to self-pMHC-II ligand than Foxp3neg conventional CD4+ T (Tconv) cells of the same specificity, potentially contributing to Treg-mediated suppression in the periphery. However, these proposed principles largely stem from the study of CD4+ T cells reactive to transgene-expressed foreign model antigens. As the expression patterns, ligand densities, and TCR-pMHCII affinities of such engineered antigen systems may not reflect those of endogenous self-antigens, it remains unclear whether the predictions of the affinity model apply to Treg cell clones reactive to natural self-ligands. To address this question, we have identified a panel of CD4+ T cell clones exhibiting varying sensitivities to the same endogenous tissue-restricted antigen (TRA), Tcaf3646-658 (“C4” peptide). C4 is an unmodified I-Ab restricted prostatic self-peptide that drives the thymic differentiation of a canonical Treg cell clone, MJ23. In other work, we also demonstrated that monoclonal MJ23 Treg cells are highly enriched in oncogene-driven prostate tumors, indicating that the C4 peptide is a naturally occurring tumor-associated antigen. Our new data using C4/I-Ab tetramers demonstrate that, in prostate-tumor-bearing mice, C4-reactive Treg and Tconv cells coexist in the tumor-draining lymph nodes, yet only the former is detected within the tumor infiltrate. Whether TCR-pMHCII affinity contributes to Tconv cell exclusion from prostate tumors remains unclear. Thus, this proposal seeks to define the role of TCR- pMHCII affinity in the thymic and peripheral selection of CD4+ T cells reactive to the natural TRA and tumor- associated antigen C4. The studies in Aim 1 will provide the first evidence testing the "TCR affinity" model for T cell clones reactive to a natural self-peptide that directs tTreg cell differentiation, offering a unique opportunity to validate and/or upend existing paradigms of thymic selection. The studies in Aim 2 mice will yield unique mechanistic insights into the factors driving the peripheral selection of TRA-reactive Treg and Tconv cells, and the selective enrichment of the former into the tumor microenvironment. Collectively, this work will leverage a novel and physiologically relevant TCR-ligand system to understand the impact of TCR-pMHCII affinity on the fundamental mechanisms by which immune tolerance is established and enforced.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$1,006 )
2024	2022	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	000	3	10/31/2023	NON-COMPETING CONTINUATION	-$1,006
														Subtotal = -$1,006

Issue Date FY: 2023 ( Subtotal = -$516 )
2023	2022	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	000	3	8/1/2023	NON-COMPETING CONTINUATION	-$516
														Subtotal = -$516

Issue Date FY: 2022 ( Subtotal = $51,752 )
2022	2022	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	000	3	12/14/2021	NON-COMPETING CONTINUATION	$51,036
2022	2022	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	001	3	5/30/2022	NON-COMPETING CONTINUATION	$716
														Subtotal = $51,752

Issue Date FY: 2021 ( Subtotal = $51,036 )
2021	2021	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	001	2	2/2/2021	NON-COMPETING CONTINUATION	$516
2021	2021	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	000	2	12/3/2020	NON-COMPETING CONTINUATION	$50,520
														Subtotal = $51,036

Issue Date FY: 2020 ( Subtotal = $50,520 )
2020	2020	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	002	1	2/11/2020	NEW	$504
2020	2020	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	001	1	12/2/2019	NEW	$0
2020	2020	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	000	1	12/2/2019	NEW	$50,016
														Subtotal = $50,520

Grand Total All Awards = $151,786

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Impact of TCR-pMHC affinity on prostate-specific CD4+ T cell development and function

Award Number: F30CA247264

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 01/01/2020

PERIOD OF PERFORMANCE END DATE: 12/30/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer